Cormorant Asset Management’s Cymabay Therapeutics CBAY Stock Holding History

Cormorant Asset Management’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,800,000	Closed	-$42.5M	–	64
2023 Q4	$42.5M	Sell	1,800,000 -2,050,000	-53%	-$36.5M	2.03%	13
2023 Q3	$57.4M	Buy	3,850,000 +50,000	+1%	+$663K	3.35%	6
2023 Q2	$41.6M	Buy	3,800,000 +2,528,571	+199%	+$23.5M	2.33%	8
2023 Q1	$11.1M	Buy	+1,271,429	New	+$10.2M	0.73%	35
2017 Q4	–	Sell	-500,000	Closed	-$4.03M	–	57
2017 Q3	$4.03M	Buy	+500,000	New	+$3.38M	0.71%	38

Other funds holding CBAY

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Cormorant Asset Management's CBAY Position: Q1 2024 in Review

Cormorant Asset Management sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 1,800,000 shares — an estimated $42.5M sold.

Cormorant Asset Management first reported a position in CBAY in Q3 2017 and held it in 5 quarters. The position peaked at $57.4M in Q3 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

Cormorant Asset Management reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
Cormorant Asset Management sold 1,800,000 Cymabay Therapeutics shares in Q1 2024, an estimated $42.5M.
Cormorant Asset Management first reported a position in Cymabay Therapeutics in Q3 2017 and held it in 5 quarters.
Cormorant Asset Management's Cymabay Therapeutics position peaked at $57.4M in Q3 2023.
1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Cormorant Asset Management's 13F filing for Q1 2024, filed 15 May 2024.